Press release
IgA Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the IgA Nephropathy Treatment Landscape @ IgA Nephropathy Pipeline Outlook [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the IgA Nephropathy Pipeline Report
* On August 15, 2025, Novartis Pharmaceuticals announced the initiation of a clinical trial designed to assess the impact of BION-1301 compared with placebo on proteinuria in adults with IgA nephropathy (IgAN). The trial plans to enroll around 330 participants with biopsy-confirmed IgAN and an eGFR greater than or equal to 30 mL/min/1.73m, who will be randomized to receive either 600 mg of BION-1301 every two weeks (Q2W) or a matching placebo for a period of 104 weeks. In addition, an exploratory cohort of about 20 participants (10 per arm) with biopsy-proven IgAN and an eGFR between greater than or equal to 20 and
* On August 15, 2025, Alexion Pharmaceuticals, Inc . announced the launch of the I CAN study, which aims to recruit approximately 510 participants with IgAN who are at high risk of disease progression. Eligible participants must have been on stable standard-of-care IgAN therapies for at least three months prior to screening. Of these, around 450 participants will be randomized in a 1:1 ratio to receive either ravulizumab (weight-based IV infusion) or placebo, in addition to their background treatment.
* On August 12, 2025, Biogen announced the initiation of a study to evaluate the impact of felzartamab on proteinuria. The trial aims to gain deeper insights into the potential of felzartamab in patients with immunoglobulin A nephropathy (IgAN). Specifically, the study will target individuals experiencing proteinuria, a condition resulting from kidney damage.
* DelveInsight's IgA Nephropathy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
* The leading IgA Nephropathy Companies such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
* Promising IgA Nephropathy Pipeline Therapies such as LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO Registered , HRS-5965 and others.
Stay informed about the cutting-edge advancements in IgA Nephropathy treatments. Download for updates and be a part of the revolution in Genito Urinary System and Steroid Hormones Care @ IgA Nephropathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
IgA Nephropathy Emerging Drugs Profile
- Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective inhibitor of the endothelin A receptor (ETA) that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Chinook selected IgAN as the lead indication for atrasentan due to the role of ETA activation in driving proteinuria, mesangial cell activation, kidney inflammation and fibrosis, the hallmarks of IgAN disease progression. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of IgA Nephropathy.
- SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
SHR-2010 is a drug being studied for the treatment of Primary IgA Nephropathy. It is an injection developed by Guangdong Hengrui Pharmaceutical Co., Ltd., currently in Phase II of research. The drug is aimed at inhibiting MASP2protein. Clinical trials are ongoing to evaluate the efficacy, safety, and pharmacokinetics of SHR-2010 in patients with Primary IgA Nephropathy.
- TAK-079: Takeda
TAK-079, also known as mezagitamab, targets CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells, leading to their depletion. The rationale for using TAK-079 in IgA nephropathy is that by reducing plasma cells responsible for producing the abnormal IgA1 protein, it may help prevent the formation of pathogenic immune complexes and subsequent kidney injury. In a Phase 1b clinical trial, TAK-079 is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.
The IgA Nephropathy Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
* IgA Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.
Learn more about IgA Nephropathy Drugs opportunities in our groundbreaking IgA Nephropathy research and development projects @ IgA Nephropathy Unmet Needs [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
IgA Nephropathy Companies
Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
IgA Nephropathy Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Stay informed about how we're transforming the future of Genito Urinary System and Steroid Hormones @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the IgA Nephropathy Pipeline Report
* Coverage- Global
* IgA Nephropathy Companies- Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, and Shanghai Alebund Pharmaceuticals and others.
* IgA Nephropathy Pipeline Therapies- LNP023, Blisibimod, Intravenous Rituximab, BION-1301, Atrasentan, TARPEYO Registered , HRS-5965 and others.
* IgA Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* IgA Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of IgA Nephropathy Pipeline on our website @ IgA Nephropathy Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* IgA Nephropathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* IgA Nephropathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atrasentan: Chinook Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TAK-079: Takeda
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Inactive Products
* IgA Nephropathy Key Companies
* IgA Nephropathy Key Products
* IgA Nephropathy- Unmet Needs
* IgA Nephropathy- Market Drivers and Barriers
* IgA Nephropathy- Future Perspectives and Conclusion
* IgA Nephropathy Analyst Views
* IgA Nephropathy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=iga-nephropathy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IgA Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4152935 • Views: …
More Releases from ABNewswire
SDQ Healthcare Services Enhances In-Home Health Care in Mission and South Texas
Mission, TX - September 12, 2025 - SDQ Healthcare Services [https://sdqhomehealthcare.com/], a family-operated, CHAP-accredited, and Medicare-certified provider, is proud to announce its ongoing commitment to delivering compassionate, personalized in-home health care throughout Mission, McAllen, San Antonio, and the greater Rio Grande Valley. With a focus on dignity, respect, and individualized attention, the agency continues to be a trusted partner for families seeking reliable care for their loved ones.
Comprehensive Care at…
Frio RV Park Announces Premier Gated RV Stays in Pearsall, TX
Pearsall, TX - September 12, 2025 - Frio RV Park [https://friorvpark.com/], a gated RV community conveniently located off I-35 in Pearsall, Texas, is proud to welcome travelers and long-term guests to enjoy a peaceful, secure, and well-appointed stay in South Texas.
Thoughtfully designed with comfort and convenience in mind, Frio RV Park offers spacious pull-thru sites with 30/50 amp full hookups, shaded lots, community BBQ grills, picnic areas, and on-site laundry…
Class Community Service Elevates HOA Management Standards Across San Antonio Are …
Universal City, TX - September 12, 2025 - Class Community Service [https://ccsclassc.com/], a veteran-family-owned turnkey HOA management firm based in Universal City, Texas, is setting a new benchmark for association management across the San Antonio region. With a commitment to personalized care, transparent operations, and disciplined financial stewardship, the company is redefining how communities experience HOA management.
At the heart of Class Community Service is a simple mission: to serve associations…
Manhattan Divorce Lawyer Richard Roman Shum Explains Key Differences Between Leg …
Navigating the complexities of marriage breakdowns can be overwhelming. In a newly released article, Manhattan divorce lawyer Richard Roman Shum (https://www.romanshum.com/blog/legal-separation-vs-divorce/) of the Law Office of Richard Roman Shum, Esq addresses the crucial distinctions between legal separation and divorce in New York, offering clear guidance for individuals facing difficult marital decisions.
In the article, Manhattan divorce lawyer Richard Roman Shum outlines that legal separation allows couples to live apart while remaining…
More Releases for IgA
Multiplier Strengthens Identity Governance with Advanced IGA Solutions
Image: https://www.abnewswire.com/upload/2025/08/8c79c8224ecce453d70ad648fa16d5e9.jpg
Introduction
In today's rapidly evolving digital landscape, managing user identities and access rights has become a critical concern for businesses of all sizes. As organizations expand, ensuring the right individuals have the correct access to systems and data is essential for operational efficiency and security. Multiplier, a leader in innovative enterprise solutions, is empowering companies with comprehensive Identity Governance and Administration (IGA) solutions to address these challenges.
IGA Solutions: The Heart…
IgA Nephropathy Market Positioned for Accelerated Development Through 2032, Delv …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Pred …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Tr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
IgA Nephropathy Drugs Market Trends And Forecast 2023-2030
Innovations and Growth Propel IgA Nephropathy Drugs Market:
Global IgA Nephropathy Drugs Market Expands with Technological Advancements and Research Initiatives
The IgA nephropathy drugs market is witnessing a surge in product launches driven by advancements in technology and an upswing in research and development activities. IgA nephropathy, an autoimmune disease affecting the kidneys, results in inflammation and kidney damage due to the accumulation of antibody clumps. The market is experiencing notable growth,…
IgA Nephropathy Drugs Market Sales, Demands and Forecasts
The IgA Nephropathy Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with…
